On Wednesday, our Under the Radar Moversnewsletter suggestedsmall cap oncology stock Champions Oncology (NASDAQ: CSBR) as a buy for our short-term portfolio:
Normally we’d like for a new “turnaround” trade to be decisively above the 200-day moving average line (green) before pulling the trigger. We’re going to go ahead and step into Champions Oncology anyway, though, even without that important clue. All the other bullish clues leading up to where we are now are pretty decisive. The biggest among those is the way the buying volume has been slowly building. We also like the sustainable pace of the progress CSBR has made since mid-November.
Our Under the Radar Moversnewsletter has a further discussion about the technical chart of Champions Oncology along with a potential trading strategy:
stock market results for today: PIMCO 25+ Year Zero Coupon US Trs ETF (ZROZ)
- [By Todd Shriber, ETF Professor]
Investors with a taste more rate-sensitive bond ETF may want to consider the PIMCO 25 Yr Zro Cupn US Ty Inx Fd ETF (NYSE: ZROZ) and the Vanguard Extended Duration ETF (NYSE: EDV).
stock market results for today: Samsung Electronics Co. Ltd. (SSNLF)
- [By SEEKINGALPHA.COM]
Some of the management and investment lessons that we can learn from the exploits of NXP Semiconductors are:
Market share does not translate into profit share. Apple (NASDAQ:AAPL) is a great example where their market share in the smart phone market is lot less compared to the likes of Samsung (OTC:SSNLF), but they garner 80% of all the industry profits. There is likely to be more consolidation in the semiconductor industry given the low concentration ratio (Also, read more on this topic here – Market Concentration). NXP teaches us the importance of understanding revenue and operating income of individual business units and learning about macroeconomic trends. Be decisive, as Warren Buffett would say, don’t dawdle. And, never let a crisis go to waste.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
- [By Kumar Abhishek]
This is a “Note 7 ” (Samsung) moment for GoPro. Instead of aphone catching fire during a flight, you have a flight (drone) suddenly losing its power and crashing down. A drone weighing 2.2 pounds falling from 20-30 feet in the sky can do quite some damage to property and people. Luckily for GoPro, no related injuries or damages have been reported. But it is clear that GoPro failed to do adequate safety checks, in a haste to release the drones before the holiday season and beat the competition. Like in the case of Samsung Electronics (OTC:SSNLF) the issues with Karma drones will immensely benefit its competitors.
- [By Leo Sun]
By comparison, Sony (NYSE:SNE) was expected to sell about 2.6 million PlayStation VRs, and Samsung (NASDAQOTH:SSNLF) was expected to sell 2.3 million Gear VRs. Even Google’s new Daydream platform was projected to fuel sales of 450,000 compatible handsets. Those numbers clearly indicate that consumer demand for cheaper devices linked to smartphones or gaming consoles could continue outselling higher-end devices tethered to pricier PCs — which would be bad news for Oculus.
- [By SEEKINGALPHA.COM]
The EU also started an antitrust investigation into Qualcomm for its alleged “predatory pricing.” That investigation hinges on whether Qualcomm’s QCT segment – whose customers included Apple (NASDAQ:AAPL) and Samsung (OTC:SSNLF) – sold chipsets used in mobile phones at or below cost in order to squeeze out rivals. If the EU finds Qualcomm guilty it could fine the company up to 10% of its global revenues.
stock market results for today: CytRx Corporation(CYTR)
- [By Roberto Pedone]
Another under-$10 biotechnology player that’s starting to trend within range of triggering a major breakout trade is CytRx (CYTR), which has an oncology pipeline that includes two programs in clinical development for cancer indications: aldoxorubicin and tamibarotene. This stock has been moving to the upside during the last three months, with shares up by 21%.
If you take a look at the chart for CytRx, you’ll notice that this stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $2.27 on the downside and $2.68 on the upside. That consolidation pattern has occurred right above this stock’s 50-day and 200-day moving averages. Shares of CYTR have now started to break out above some near-term overhead resistance at $2.49 a share. That move is quickly pushing CYTR within range of triggering an even bigger breakout trade above the upper-end of its recent sideways trading chart pattern.
Market players should now look for long-biased trades in CYTR if it manages to break out above some near-term overhead resistance levels at $2.68 to $2.80 a share with high volume. Look for a sustained move or close above those levels with volume that registers near or above its three-month average action of 154,838 shares. If that breakout triggers soon, then CYTR will set up to re-test or possibly take out its next major overhead resistance levels at $3.20 to $4 a share.
Traders can look to buy CYTR off any weakness to anticipate that breakout and simply use a stop that sits right below its 200-day at $2.33 a share or below more support at $2.27 a share. One can also buy CYTR off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
stock market results for today: Polycom Inc.(PLCM)
- [By Emily Stewart]
Polycom (PLCM) is Soros’ top tech holding. As of the end of the second quarter, he owns 7.9 million shares valued at $89.2 million.
Polycom provides collaboration solutions for voice, video, and content sharing. It has a $1.7 billion market cap and trades at a P/E of 73.24.
stock market results for today: Albemarle Corporation(ALB)
- [By Monica Gerson]
Albemarle Corporation (NYSE: ALB) is estimated to post its quarterly earnings at $0.86 per share on revenue of $814.80 million.
Markit Ltd (NASDAQ: MRKT) is expected to report its quarterly earnings at $0.36 per share on revenue of $293.62 million.
- [By WWW.THESTREET.COM]
With an improving global economy, now is a great time to be a chemical company, Cramer told viewers, as he reiterated his favorites: Albemarle (ALB) and FMC Technology (FMC) .
- [By Ben Levisohn]
Albemarle (ALB) soared to the top of the S&P 500 today after beating fourth-quarter earnings and revenue forecasts.
S. MARTIN/AFP/Getty Images
Albemarle gained 9.8% to $101.50, while the S&P 500 dipped 0.3% to 2,363.64.
Baird’s Ben Kallo and team liked what they saw from Albemarle:
Reiterate Outperform rating after results beat and guidance exceeded estimates. ALB continues to see strong Lithium demand and pricing, expects Refining Solutions to return to earnings growth in 2017 driven by stronger HPC demand, and bolstered its balance sheet with the sale of Surface Treatment. Additionally, although Bromine is expected to be flat y/y, the segment should generate strong FCF for Lithium investment. We expect shares to trade higher as ALB continues to separate itself from specialty chemical comps with leading market positions and strong revenue growth.
Albemarle’s market capitalization rose to $11.4 billion today from $10.4 billion yesterday.
stock market results for today: Immersion Corporation(IMMR)
- [By Jim Robertson]
On Thursday, our Under the Radar Movers newsletter suggested shorting small cap technology stock Immersion Corporation (NASDAQ: IMMR):
We love how well developed the selling of Immersion shares has been. Rather than a sharp, v-shaped reversal — which may or may not follow through — we’ve seen a bowl-shaped transition from an uptrend to a downtrend. This ups the odds of downside follow-through, as there’s been no price “shock” to invite a sudden wave of buying.